History for Cisplatin and Pemetrexed
This web page gives more detail about a specific example
discussed in Deriving Chemosensitivity from Cell
Lines: Forensic Bioinformatics and Reproducible Research in High-Throughput
Biology by Keith A. Baggerly and Kevin R. Coombes.
The main page for this paper is
here.
One of the case studies involves
signatures of response for cisplatin and pemetrexed. This case
study was important because these drugs were being used in
clinical trials at the time we submitted our paper to the
Annals of Applied Statistics. However, this was not
the first time we had identified these problems. We communicated
with journals involved in 2007 and 2008; at least one of these
communicated with Drs. Potti and Nevins at the time -- at least
a year and a half before. A full summary is
here.
Timeline of Events
Nov 5, 2007: We submit a
correspondence and
a
supplementary report
to the Journal of Clinical Oncology (JCO). JCO's
acknowledgement
of receipt.
Dec 14, 2007: JCO
declines our
correspondence.
Dec 17, 2007: We
ask why.
Jan 4, 2008: JCO
declines our
correspondence again.
May 30, 2008: We submit a
correspondence and
figure describing
various problems, including those with cisplatin and pemetrexed,
to Nature Medicine. Nature Medicine's
acknowledgement
of receipt.
Jun 2, 2008: Nature Medicine
asks
permission to share our correspondence with Potti et al.,
which we grant.
Jun 11, 2008: Nature Medicine
declines
our correspondence, citing the "detailed response" given by
Drs. Potti and Nevins.